At BioStem Technologies, healthy, safe and effective recovery of patients is our main focus. All of our products are produced in our AATB® accredited lab in accordance with the FDA regulations for Good Tissue Practices.
Perinatal Tissue Allografts
Human perinatal tissue derived allografts have been used in allogeneic transplants since the beginning of the last century. Their anti-inflammatory, anti-microbial, and immune privileged properties make them ideal candidates for novel applications across a wide range of medical disciplines. With continued clinical success, perinatal tissues are increasingly adopted as a preferred treatment platform.
BioStem Technologies suite of perinatal tissue-derived allografts include RHEO™, OROPRO™, AEON™, VENDAJE™, VENDAJE™ AC and VENDAJE™ OPTIC. They are designated as Human Cell, Tissue, and Cellular and Tissue-Based Products (HCT/P) by the U.S. Food and Drug Administration (FDA), are minimally manipulated, and are produced in accordance with the FDA regulations for Good Tissue Practices (21 CFR 1270, 1271).
